cancers

an Open Access Journal by MDPI

IMPACT FACTOR 4.5

Indexed in: PubMed

CITESCORE 8.0

Novel Insights into the Molecular Mechanisms of Treatment Resistance and Predictive Biomarkers in Metastatic Prostate Cancer

Guest Editors:

Dr. Albert Font
Badalona–Badalona Applied Research Group in Oncology (B·ARGO), Catalan Institute of Oncology, 08916 Badalona, Spain

Dr. Vicenç Ruiz de Porras
1. Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Ctra. Can Ruti-Camí de les Escoles s/n, 08916 Badalona, Spain
2. Germans Trias i Pujol Research Institute (IGTP), Ctra. Can Ruti-Camí de les escoles s/n, 08916 Badalona, Spain

Deadline for manuscript submissions:
closed (30 April 2023)

Message from the Guest Editors

Prostate cancer (PC) is the most common malignancy in men and a major cause of cancer death. For patients with PC who experience disease relapse after local therapy or for those with metastatic disease, androgen deprivation therapy (ADT) is the backbone of systemic therapy. However, almost all metastatic patients progress to an incurable metastatic castration-resistant prostate cancer (mCRPC), defined as radiographic progression and/or a rise in prostate-specific antigen (PSA) despite having a castrate level of testosterone. Although several new options for the treatment of mCRPC have been approved in the last decade—the CYP17 inhibitor abiraterone, the androgen receptor antagonist enzalutamide, the taxane cabazitaxel, the immunotherapy sipuleucel-T, the alpha-emmitter radium-223 as well as PARP inhibitors and PSMA radioligands—unfortunately, not all patients initially respond to these therapies, while nearly all of them develop resistance. Thus, understanding the molecular and clinical mechanisms leading to therapy resistance and determine new predictive biomarkers is crucial.

cancers

IMPACT FACTOR 4.5 | Indexed in: PubMed | CITESCORE 8.0

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
𝕏@Cancers_MDPI